Trials / Terminated
TerminatedNCT05652907
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients With Chronic Widespread Musculoskeletal Nociplastic Pain Associated With Idiopathic Mast Cell Activation Syndrome (Disorder)
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Quantum Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal nociplastic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FSD201 | Tablets for oral administration. |
| DRUG | Placebo | Placebo tablets matched to FSD201 for oral administration. |
Timeline
- Start date
- 2023-01-19
- Primary completion
- 2023-05-24
- Completion
- 2023-05-24
- First posted
- 2022-12-15
- Last updated
- 2023-07-06
Locations
3 sites across 2 countries: United States, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05652907. Inclusion in this directory is not an endorsement.